MedTrace Logo

Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer

NCT00760370 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-12-07

No results posted yet for this study

Summary

The investigators major aim is to determine whether there is a difference in the retention of zoledronic acid in multiple myeloma patients, compared to patients with breast cancer metastasis to bone. In addition the investigators wish to analyze if the retention of zoledronic acid is correlated to the extent of bone resorption/formation, and if there is a tendency to changes in retention with sequential treatment.

Conditions

Interventions

DRUG

Zoledronic Acid

4 mg intravenous (iv), one treatment

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Novartis

    collaborator INDUSTRY

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Torben Plesner, MD, PhD · Vejle Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760370 on ClinicalTrials.gov